INS and Alzheimer disease: Importantly, GSK‐3 is a stress kinase that can also impair insulin signaling and glucose metabolism, and inhibition of GSK‐3 is well known to improve whole‐body insulin resistance and glucose metabolism (Nikoulina et al. 2002) and, as such, is being investigated as a potential AD therapy (Pal et al. 2021).